A Study of INCB039110 in Combination with Corticosteroids for the Treatment of Acute Graft Versus Host Disease

Overview

Información sobre este estudio

The purpose of this study is to determine if INCB039110 in combination with corticosteroids is safe and tolerable for treating patients with Grade IIB-IVD acute graft-versus-host disease (GVHD).

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

  • Have undergone first allo-HSCT from any donor source (matched unrelated donor, sibling, haploidentical) using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies
  • Recipients of nonmyeloablative and myeloablative transplants
  • Clinically suspected Grades IIB to IVD acute GVHD as per modified MN-CIBMTR criteria, occurring after allo-HSCT with any conditioning regimen and any anti-GVHD prophylactic program
  • May, but are not required to, have previously received corticosteroids for acute GVHD
  • Evidence of myeloid engraftment
    • Use of growth factor supplementation is allowed

Exclusion Criteria

  • Has received more than 1 hematopoietic stem cell transplantation
  • Has progressed on more than 2 prior treatment regimens for acute GVHD
  • Presence of an active uncontrolled infection
  • Has relapsed primary disease, or has been treated for relapse after the allogeneic hematopoietic stem-cell transplantation (allo-HSCT) was performed
  • Inadequate recovery from toxicity and/or complications from the prior allo-HSCT
  • Any corticosteroid therapy (for indications other than GVHD) at doses > 1 mg/kg per day methylprednisolone or equivalent within 7 days of randomization
  • Previously received JAK inhibitor therapy for any indication

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Jeanne Palmer, M.D.

Comunícate con nosotros para obtener el estatus más reciente

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publicaciones

Publications are currently not available